Meropenem Kabi (Meropenem Anhydrous)

Meropenem is a broad‑spectrum carbapenem used for serious bacterial infections across several organ systems.

• Complicated intra‑abdominal infections: provides rapid bacterial eradication to resolve intra‑abdominal sepsis.
• Complicated urinary tract infections: eliminates resistant Gram‑negative pathogens causing severe UTIs.
• Hospital‑acquired pneumonia: treats lung infections acquired during hospitalization, including those caused by multidrug‑resistant organisms.
• Ventilator‑associated pneumonia: targets pathogens associated with mechanical ventilation‑related lung infection.
• Severe sepsis and septic shock: offers timely bactericidal activity to control systemic infection.
• Meningitis (off‑label): penetrates the cerebrospinal fluid to treat bacterial meningitis when other options are limited.

• Meropenem inhibits bacterial cell wall synthesis by binding with high affinity to penicillin‑binding proteins (PBPs). This binding disrupts the final transpeptidation step of peptidoglycan cross‑linking, leading to weakened cell walls, osmotic instability, and ultimately bacterial cell lysis and death. Its broad spectrum includes many Gram‑negative, Gram‑positive, and anaerobic organisms.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: may be watery and self‑limited.
• Rash: localized skin erythema or pruritus.
• Infusion site phlebitis: pain or redness at the IV site.
• Headache: transient mild headache.
• Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

• Seizures: especially in patients with renal impairment or high doses.
• Clostridioides difficile‑associated colitis: severe diarrhea with pseudomembranous colitis.
• Anaphylaxis: acute, potentially life‑threatening allergic reaction.
• Renal toxicity: acute kidney injury in susceptible individuals.
• Hematologic abnormalities: thrombocytopenia or neutropenia.
• Stevens‑Johnson syndrome: rare severe skin reaction.

Meropenem should be used with careful clinical monitoring and appropriate dose adjustments.

• Renal function: assess creatinine clearance and adjust dose in renal impairment.
• Hepatic function: monitor liver enzymes in patients with pre‑existing liver disease.
• Neonates and infants: use with caution; dosing differs from adults.
• Concomitant valproic acid: increased risk of seizures; avoid combination.
• Pregnancy: safety category unknown; weigh potential benefits against risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several drugs, requiring vigilance.

Major Interactions (Avoid)

• Valproic acid: may lower seizure threshold and increase neurotoxicity.
• Other carbapenems: concurrent use can increase toxicity without added benefit.
• High‑dose aminoglycosides: additive nephrotoxicity risk.

Moderate Interactions (Monitor Closely)

• Loop diuretics: may exacerbate renal impairment.
• NSAIDs: potential for reduced renal clearance.
• Anticoagulants (e.g., warfarin): monitor INR for possible alterations.
• Probenecid: may decrease renal excretion of meropenem, increasing plasma levels.